✦Corporate brand & media services✦Made in Virginia Beach since 1997✦Boards engagement today people · AI✦
Rotting at the dockGrew revenue 12.5% in FY2025 to $5 million, operating margin -268% against a 1.2% median for surgical & medical instruments & apparatus, equity 16.8% of assets.
Last filing10-Q, 16 Nov 2026
🫧 Edgar looked up Picard Medical, Inc. ($PMI). Last filing: 10-Q, 2026-11-16. 39 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $4.9M (FY2025). Experience: revenue up 12.5% on the year; operating margin -268.4%, up from -312.3%. Soundness: equity 16.8% of assets, return on equity -712.6%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $4.1M and $7.3M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -268.4% against a 1.2% median; growth 12.5% against 11.6%.
Read from its own SEC filings · nothing written, nothing inferred
| Cash flow (op · inv · fin · free) | −$16M · — · $27M · — |
| Investment book (cash · short · long) | $7M · — · — · current ratio 1.11 |
| Fiscal year end | 2025-12-31 |
| Revenue | $5M |
| Revenue, on the year | 12.5% |
| Revenue, a year over the record | — |
| Operating margin | −268.4% |
| Operating margin, prior year | −312.3% |
| Net margin | −546.6% |
| Research and development | $3M · 61.7% of revenue |
| Total debt | — |
| Equity of assets | 16.8% |
| Return on equity | −712.6% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.75 |
| Book value per share | $0.10 |
| Revenue per share | $0.14 |
| Shares outstanding | 36,233,084 |
| Audited years read | 2 |
Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.
Classic signals · fiscal 2025Altman Z″ -14.26 distress zone 1968Piotroski F 4 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -65.4% earnings backed by cash 1996DuPont ROE needs net income, revenue and two years of assets and equity
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health watch · 12 monthsExchange listing notice or transfer ×3Late quarterly report noticeDirector or officer change ×4
Versus peersoperating margin −268.4% vs a 1.2% median · revenue growth 12.5% vs 11.6% 60 surgical & medical instruments & apparatus filers
Trend · last year to this▲operating margin −312.3% → −268.4% · ▲revenue $4.4M → $4.9M
| # | Company | Condition | Operating margin | Revenue growth | Sales | |
|---|---|---|---|---|---|---|
| 1 | ![]() | Lemaitre VascularLMAT | New ship | 27.2% | 13.5% | $249.6M |
| 2 | ![]() | DexcomDXCM | New ship | 19.6% | 15.6% | $4.7B |
| 3 | ![]() | StrykerSYK | New ship | 19.5% | 11.2% | $25.1B |
| 4 | ![]() | MedlineMDLN | New ship | 7.8% | 11.5% | $28.4B |
| 5 | ![]() | ResMedRMD | Sound ship | 33.4% | 9.9% | $5.7B |
| 6 | ![]() | West Pharmaceutical ServicesWST | Sound ship | 19.0% | 6.3% | $3.1B |
| 7 | ![]() | 3M CompanyMMM | Sound ship | 18.6% | 1.5% | $24.9B |
| 8 | ![]() | Boston ScientificBSX | Sound ship | 18.0% | 19.9% | $20.1B |
| 9 | ![]() | InsuletPODD | Sound ship | 17.5% | 30.7% | $2.7B |
| 10 | ![]() | Interpace BiosciencesIDXG | Sound ship | 10.5% | −17.5% | $38.7M |
| 11 | ![]() | Infusystem HoldingsINFU | Sound ship | 8.3% | 6.4% | $143.4M |
| 12 | ![]() | NephrosNEPH | Sound ship | 6.1% | 32.7% | $18.8M |
| 13 | ![]() | AngioDynamicsANGO | Sound ship | −12.5% | 9.5% | $320.2M |
| 14 | ![]() | Bluejay DiagnosticsBJDX | Sound ship | −3741.5% | — | $0.2M |
| 15 | ![]() | Modular MedicalMODD | Sound ship | — | — | $0.0M |
| 16 | ![]() | Microbot MedicalMBOT | Weathered boat | 782.8% | −88.5% | $0.1M |
| 17 | ![]() | Pro-DexPDEX | Weathered boat | 16.8% | 16.5% | $77.5M |
| 18 | ![]() | Sanuwave HealthSNWV | Weathered boat | 11.2% | 35.0% | $44.1M |
| 19 | ![]() | MiniMed GroupMMED | Weathered boat | −6.1% | 14.3% | $3.1B |
| 20 | ![]() | iRhythm HoldingsIRTC | Weathered boat | −7.7% | 26.2% | $747.1M |
| 21 | ![]() | SI-Bone, Inc.SIBN | Weathered boat | −11.1% | 20.2% | $200.9M |
| 22 | ![]() | NovoCure LimitedNVCR | Weathered boat | −23.5% | 8.3% | $655.4M |
| 23 | ![]() | Integra Lifesciences HoldingsIART | Weathered boat | −30.2% | 1.5% | $1.6B |
| 24 | ![]() | Procept BioRoboticsPRCT | Weathered boat | −33.7% | 37.2% | $308.1M |
| 25 | ![]() | Beta BionicsBBNX | Weathered boat | −71.5% | 53.9% | $100.3M |
| 26 | ![]() | enVVeno MedicalNVNO | Weathered boat | −24566.5% | −83.3% | $0.0M |
| 27 | ![]() | Autonomix MedicalAMIX | Weathered boat | — | — | $0.0M |
| 28 | ![]() | Odyssey HealthODYY | Weathered boat | — | — | $0.0M |
| 29 | ![]() | GlucotrackGCTK | Old boat | 1685.6% | 378.3% | $0.2M |
| 30 | ![]() | Teleflex IncorporatedTFX | Old boat | 5.9% | 17.2% | $2.0B |
| 31 | ![]() | Accuray IncorporatedARAY | Old boat | −6.6% | −12.3% | $401.9M |
| 32 | ![]() | SkinHealth SystemsSKIN | Old boat | −6.9% | −10.0% | $300.8M |
| 33 | ![]() | Sonoma PharmaceuticalsSNOA | Old boat | −12.6% | 36.7% | $19.5M |
| 34 | ![]() | CarlsmedCARL | Old boat | −60.5% | 85.9% | $50.5M |
| 35 | ![]() | CVRxCVRX | Old boat | −90.5% | 10.4% | $56.7M |
| 36 | ![]() | Orchestra BioMed HoldingsOBIO | Old boat | −154.7% | 1169.2% | $33.5M |
| 37 | ![]() | Profound MedicalPROF | Old boat | −256.3% | 50.7% | $16.1M |
| 38 | ![]() | Intelligent Bio SolutionsINBS | Old boat | −299.1% | 38.1% | $4.2M |
| 39 | ![]() | Tenon MedicalTNON | Old boat | −324.3% | 20.4% | $3.9M |
| 40 | ![]() | Beyond AirXAIR | Old boat | −378.2% | 107.3% | $7.7M |
| 41 | ![]() | InspireMDNSPR | Old boat | −552.6% | 28.1% | $9.0M |
| 42 | ![]() | FemasysFEMY | Old boat | −767.0% | 40.8% | $2.3M |
| 43 | ![]() | Harvard Apparatus Regenerative TechnologyHRGN | Old boat | −982.2% | 63.7% | $0.7M |
| 44 | ![]() | SeaStar Medical HoldingICU | Old boat | −986.6% | 814.1% | $1.2M |
| 45 | ![]() | Lucid DiagnosticsLUCD | Old boat | −1054.8% | 8.3% | $4.7M |
| 46 | ![]() | ProfusaPFSA | Old boat | −4500.0% | — | $0.1M |
| 47 | ![]() | VivosRDGL | Old boat | −4628.7% | 144.3% | $0.1M |
| 48 | ![]() | CO-DiagnosticsCODX | Old boat | −8058.8% | −84.1% | $0.6M |
| 49 | ![]() | Pulse BiosciencesPLSE | Old boat | −21982.6% | — | $0.3M |
| 50 | ![]() | PAVmedPAVM | Old boat | −30712.7% | −97.6% | $0.1M |
| 51 | ![]() | StimCell EnergeticsSTME | Old boat | — | −100.0% | $0.0M |
| 52 | ![]() | Fractyl HealthGUTS | Old boat | — | −100.0% | $0.0M |
| 53 | ![]() | Global Innovative PlatformsGIPL | Old boat | — | — | $0.0M |
| 54 | ![]() | Adagio Medical Holdings, Inc.ADGM | Old boat | — | −100.0% | $0.0M |
| 55 | ![]() | BiotricityBTCY | Rotting at the dock | 10.6% | 16.0% | $16.0M |
| 56 | ![]() | Premier Air Charter HoldingsPREM | Rotting at the dock | −8.5% | 53.6% | $31.9M |
| 57 | ![]() | SS Innovations InternationalSSII | Rotting at the dock | −19.3% | 105.7% | $42.5M |
| 58 | ![]() | NeuroneticsSTIM | Rotting at the dock | −21.1% | 99.2% | $149.2M |
| 59 | ![]() | NexGelNXGL | Rotting at the dock | −29.3% | 31.5% | $11.4M |
| 60 | ![]() | CytosorbentsCTSO | Rotting at the dock | −39.8% | 4.1% | $37.1M |
| 61 | ![]() | Tela BioTELA | Rotting at the dock | −42.0% | 15.8% | $80.3M |
| 62 | ![]() | Spectral AIMDAI | Rotting at the dock | −43.8% | −33.6% | $19.6M |
| 63 | ![]() | Nuo TherapeuticsAURX | Rotting at the dock | −76.0% | 142.7% | $3.3M |
| 64 | ![]() | Invo FertilityIVF | Rotting at the dock | −105.8% | 4.3% | $6.8M |
| 65 | ![]() | Vivos TherapeuticsVVOS | Rotting at the dock | −114.1% | 16.0% | $17.4M |
| 66 | ![]() | DarioHealthDRIO | Rotting at the dock | −163.9% | −17.3% | $22.4M |
| 67 | ![]() | Picard MedicalPMI · this company | Rotting at the dock | −268.4% | 12.5% | $4.9M |
| 68 | ![]() | Osr HealthOSRH | Rotting at the dock | −631.0% | −17.7% | $2.9M |
| 69 | ![]() | PetVivo HoldingsPETV | Rotting at the dock | −793.9% | 0.8% | $1.1M |
| 70 | ![]() | Sintx TechnologiesSINT | Rotting at the dock | −1053.1% | −64.7% | $1.0M |
| 71 | ![]() | Flyte AviationVJET | Rotting at the dock | −2581.6% | 95.0% | $0.8M |
From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.
Tied up at the dock.
🌊 Visit the Bay →Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·
Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time info@pops4.comNine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.